Navigation Links
Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
Date:12/10/2012

lammatory and neuropathic pain states and these fundamental studies support not only the EMA401 clinical program but also Spinifex's ongoing AT2 receptor antagonist drug discovery program.

Spinifex Pharmaceuticals

Spinifex Pharmaceuticals is an Australian biotechnology company developing new drug candidates for the treatment and management of pain.

Established in 2005 and based in Melbourne, Spinifex has applied its world-class drug development capabilities to advance product candidates. Its lead product EMA401 is under development as a potential first-in-class oral treatment for chronic pain, including neuropathic pain, without CNS side effects. Spinifex's Phase 2 program for EMA401 includes clinical trials in a number of neuropathic pain conditions. Spinifex investors are GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest.

http://www.spinifexpharma.com.au

For more information please contact:

Company
Dr Tom McCarthy
CEO Spinifex Pharmaceuticals
Tel: +61-(0)3-9938-1205
Email: tom.mccarthy@spinifexpharma.com.au

Media
Chris Gardner/Nina Enegren
Citigate Dewe Rogerson
Tel: +44-(0)20-7638-9571
Email: nina.enegren@citigatedr.co.uk


'/>"/>
SOURCE Spinifex Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Seahorse Bioscience Announces Asia Mito 2012 Travel Award Winners Advancing Cell Metabolism Research
2. Blue Belt Technologies Announces Golden Jubilee National Hospital Completes Initial NavioPFS Unicondylar Knee Replacement Surgery
3. Northwest Biotherapeutics Announces Public Offering of Common Stock and Warrants, and Listing on NASDAQ
4. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. PTC Therapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Ataluren in Duchenne Muscular Dystrophy
6. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
7. OrthoAccel Technologies, Inc. Announces Appointment of New Chief Financial Officer
8. Cerecor Announces Option to Johns Hopkins Brain Science Institute DAAO Inhibitor Platform
9. Savient Announces the Election of Robert G. Savage to its Board of Directors
10. Harrington Discovery Institute at University Hospitals Case Medical Center Announces Grant Funding to Physician-Scientists at Major Academic Medical Centers to Support New Drug Development
11. Braincells, Inc. Announces the Successful Completion of a Multiple Ascending Dose Study of BCI-838, a Group II mGluR2/3 Antagonist, and the Companys Plans for a Proof-of-Concept Study in Patients with Treatment-Resistant Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
(Date:1/14/2014)... HILLSBORO, Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- ... and a targeting guide with accompanying instrumentation to place ... new adjunct to the soft tissue (e.g. ligament) repair ... soft tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... WASHINGTON, Dec. 6, 2011  BodyMedia, the leading developer ... Qualcomm Life, a wholly owned subsidiary of Qualcomm ... BodyMedia FIT ™ LINK Armband ... BodyMedia Armband users to share wireless health data, ...
... 6, 2011  Echo Therapeutics, Inc. (Nasdaq: ECTE ... a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system ... today announced a registered direct equity financing of approximately ... of one share of its common stock and a ...
Cached Medicine Technology:BodyMedia Plans to Join Qualcomm Life's Wireless Health 2net Ecosystem 2BodyMedia Plans to Join Qualcomm Life's Wireless Health 2net Ecosystem 3BodyMedia Plans to Join Qualcomm Life's Wireless Health 2net Ecosystem 4Echo Therapeutics Announces Pricing of $5.4 Million Registered Direct Equity Financing 2Echo Therapeutics Announces Pricing of $5.4 Million Registered Direct Equity Financing 3
(Date:7/9/2014)... types of cancer sends the protein factories in our ... uncontrolled growth, new research suggests. , Scientists at The ... responsible for ratcheting up activity of the endoplasmic reticulum ... blocks cancer cells need to keep growing. , A ... the flow of messages to the endoplasmic reticulum telling ...
(Date:7/9/2014)... that fecal transplantation is effective and safe for treating ... the result of a study led by Colleen Kelly, ... Medicine at The Women,s Medicine Collaborative. The study and ... print in the American Journal of Gastroenterology . ... , has increased to epidemic proportions over the past ...
(Date:7/9/2014)... There has been a sharp increase in the ... using MyChart, the online, interactive service that allows patients ... healthcare providers, schedule appointments, and renew prescriptions. , Over ... MyChart each year increased five-fold, while the ... 10-fold, according to a study by Dr. David ...
(Date:7/9/2014)... Allergy and Infectious Diseases (NIAID), part of the ... clinical trial of CRS3123, an investigational oral antibiotic ... C. difficile ) infection. CRS3123 (previously known as ... difficile growth while sparing normal intestinal bacteria. , ... 30 healthy men and women ages 18 to ...
(Date:7/9/2014)... , , , , , ... , , , , , ... binaural recording using KEMAR, the weapon was an SA80 assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... ... , , , , ... , , , , , ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
... Oct. 24 NetSuite Inc., a ... suites that provide,Accounting/ERP (Enterprise Resource Planning), ... for small and medium-sized,businesses and divisions ... NetSuite,partners and solution providers have introduced, ...
... THOR ), a world leader in products to treat,cardiovascular ... for the third quarter of fiscal 2007 on Thursday, ... call to discuss its financial,results and operating activities open ... (11:30 a.m., Eastern Daylight Time), Thursday,November 1, hosted by ...
... Cancer Prevention Expert and First Hispanic President ... Communications Expert Marion E. Morra to,Lead Volunteer Board ... American Cancer,Society, the nation,s largest voluntary health organization, ... Board of Directors during its,annual meeting held this ...
... 25 3M and,Zargis Medical Corp., a spin-off ... a majority-owned subsidiary of Speedus Corp. (Nasdaq: ... involving Zargis,heart sound analysis software and 3M Littmann,s ... support 3M in its efforts to develop a,next-generation ...
... (E) Executive Director, ... American Public Health Association, WASHINGTON, Oct. 25 ... House of Representatives,today to support legislation to reauthorize the Children,s ... points of,opposition. They,ve come up with a plan that even ...
... October 25, 2007 - Postmenopausal women are at ... the chronic health conditions associated with obesity become ... of Obstetric, Gynecologic, & Neonatal Nursing reviews the ... that are relevant to postmenopausal women. The article ...
Cached Medicine News:Health News:NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 2Health News:NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 3Health News:NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 4Health News:NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 5Health News:NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 6Health News:NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 7Health News:Thoratec Schedules Third Quarter Conference Call, Webcast 2Health News:New Volunteers Selected to Lead American Cancer Society 2Health News:New Volunteers Selected to Lead American Cancer Society 3Health News:New Volunteers Selected to Lead American Cancer Society 4Health News:New Volunteers Selected to Lead American Cancer Society 5Health News:New Volunteers Selected to Lead American Cancer Society 6Health News:3M and Zargis Announce Global Marketing Alliance 2Health News:3M and Zargis Announce Global Marketing Alliance 3Health News:3M and Zargis Announce Global Marketing Alliance 4
125I radioimmunoassay, Simple extraction procedure, Ready-to-use calibrators, Less than 0.1% crossreactivity with DHEA-SO4, 2-hour single incubation, 37C, Calibration Range: 0.5 30 ng/mL...
Inquire...
EL-RF/3 is for measurement of IgM, IgG, IgA RF with high specificity for rheumatoid arthritis....
Rapid latex slide agglutination assay for the qualitative and semi-quantitative determination of Rheumatoid Factors in human serum....
Medicine Products: